SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung.

Although superiority of synthetic surfactant over animal-driven surfactant has been known, there is no synthetic surfactant commercially available at present. Many trials have been made to develop synthetic surfactant comparable in function to animal-driven surfactant. The efficacy of treatment with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Atsuyasu Sato, Machiko Ikegami
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7399133ee0354fc6b63dc4ced2090fa9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7399133ee0354fc6b63dc4ced2090fa9
record_format	dspace
spelling	oai:doaj.org-article:7399133ee0354fc6b63dc4ced2090fa92021-11-18T07:12:36ZSP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung.1932-620310.1371/journal.pone.0039392https://doaj.org/article/7399133ee0354fc6b63dc4ced2090fa92012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22808033/?tool=EBIhttps://doaj.org/toc/1932-6203Although superiority of synthetic surfactant over animal-driven surfactant has been known, there is no synthetic surfactant commercially available at present. Many trials have been made to develop synthetic surfactant comparable in function to animal-driven surfactant. The efficacy of treatment with a new synthetic surfactant (CHF5633) containing dipalmitoylphosphatidylcholine, phosphatidylglycerol, SP-B analog, and SP-C analog was evaluated using immature newborn lamb model and compared with animal lung tissue-based surfactant Survanta. Lambs were treated with a clinical dose of 200 mg/kg CHF5633, 100 mg/kg Survanta, or air after 15 min initial ventilation. All the lambs treated with air died of respiratory distress within 90 min of age. During a 5 h study period, Pco(2) was maintained at 55 mmHg with 24 cmH(2)O peak inspiratory pressure for both groups. The preterm newborn lamb lung functions were dramatically improved by CHF5633 treatment. Slight, but significant superiority of CHF5633 over Survanta was demonstrated in tidal volume at 20 min and dynamic lung compliance at 20 and 300 min. The ultrastructure of CHF5633 was large with uniquely aggregated lipid particles. Increased uptake of CHF5633 by alveolar monocytes for catabolism was demonstrated by microphotograph, which might be associated with the higher treatment dose of CHF5633. The higher catabolism of CHF5633 was also suggested by the similar amount of surfactant lipid in bronchoalveolar lavage fluid (BALF) between CHF5633 and Survanta groups, despite the 2-fold higher treatment dose of CHF5633. Under the present ventilation protocol, lung inflammation was minimal for both groups, evaluated by inflammatory cell numbers in BALF and expression of IL-1β, IL-6, IL-8, and TNFα mRNA in the lung tissue. In conclusion, the new synthetic surfactant CHF5633 was effective in treating extremely immature newborn lambs with surfactant deficiency during the 5 h study period.Atsuyasu SatoMachiko IkegamiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 7, p e39392 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Atsuyasu Sato Machiko Ikegami SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung.
description	Although superiority of synthetic surfactant over animal-driven surfactant has been known, there is no synthetic surfactant commercially available at present. Many trials have been made to develop synthetic surfactant comparable in function to animal-driven surfactant. The efficacy of treatment with a new synthetic surfactant (CHF5633) containing dipalmitoylphosphatidylcholine, phosphatidylglycerol, SP-B analog, and SP-C analog was evaluated using immature newborn lamb model and compared with animal lung tissue-based surfactant Survanta. Lambs were treated with a clinical dose of 200 mg/kg CHF5633, 100 mg/kg Survanta, or air after 15 min initial ventilation. All the lambs treated with air died of respiratory distress within 90 min of age. During a 5 h study period, Pco(2) was maintained at 55 mmHg with 24 cmH(2)O peak inspiratory pressure for both groups. The preterm newborn lamb lung functions were dramatically improved by CHF5633 treatment. Slight, but significant superiority of CHF5633 over Survanta was demonstrated in tidal volume at 20 min and dynamic lung compliance at 20 and 300 min. The ultrastructure of CHF5633 was large with uniquely aggregated lipid particles. Increased uptake of CHF5633 by alveolar monocytes for catabolism was demonstrated by microphotograph, which might be associated with the higher treatment dose of CHF5633. The higher catabolism of CHF5633 was also suggested by the similar amount of surfactant lipid in bronchoalveolar lavage fluid (BALF) between CHF5633 and Survanta groups, despite the 2-fold higher treatment dose of CHF5633. Under the present ventilation protocol, lung inflammation was minimal for both groups, evaluated by inflammatory cell numbers in BALF and expression of IL-1β, IL-6, IL-8, and TNFα mRNA in the lung tissue. In conclusion, the new synthetic surfactant CHF5633 was effective in treating extremely immature newborn lambs with surfactant deficiency during the 5 h study period.
format	article
author	Atsuyasu Sato Machiko Ikegami
author_facet	Atsuyasu Sato Machiko Ikegami
author_sort	Atsuyasu Sato
title	SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung.
title_short	SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung.
title_full	SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung.
title_fullStr	SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung.
title_full_unstemmed	SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung.
title_sort	sp-b and sp-c containing new synthetic surfactant for treatment of extremely immature lamb lung.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/7399133ee0354fc6b63dc4ced2090fa9
work_keys_str_mv	AT atsuyasusato spbandspccontainingnewsyntheticsurfactantfortreatmentofextremelyimmaturelamblung AT machikoikegami spbandspccontainingnewsyntheticsurfactantfortreatmentofextremelyimmaturelamblung
_version_	1718423795541213184

SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung.

Ejemplares similares